13F Data
13F filer · CIK 1909617

QIMING U.S. VENTURES MANAGEMENT, LLC

BELLEVUE, WA · filing since Q4 2021 · last filing Nov 10, 2025
Reported value
$55.6M
+$32.0M vs prior
Positions
4
New / sold out
0 / 2
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $1.6M
Top-10 weight
100.0%

Biggest buys vs Q2 2025

No new or increased positions this quarter.

Biggest sells vs Q2 2025

ChangeSecurityShares changeChange %Est. trade value
Sold outVENTYX BIOSCIENCES INC-412,225-100.0%$-882.2K
Sold outHILLEVAX INC-372,615-100.0%$-741.5K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2021: $217.3MQ1 2022: $106.4MQ2 2022: $72.0MQ3 2022: $68.8MQ4 2022: $75.6MQ1 2023: $82.6MQ2 2023: $95.2MQ3 2023: $75.3MQ4 2023: $109.2MQ1 2024: $89.7MQ2 2024: $52.6MQ3 2024: $51.4MQ4 2024: $51.1MQ1 2025: $23.1MQ2 2025: $23.6MQ3 2025: $55.6M
Q4 2021Q3 2025

Holdings · Q3 2025

#SecuritySharesValueWeight
1TOURMALINE BIO INCCOM741,691$35.5M63.76%
2KORRO BIO INCCOM368,085$17.6M31.68%
3JASPER THERAPEUTICS INCCOM NEW928,964$2.2M3.97%
4KEZAR LIFE SCIENCES INCCOM NEW82,871$323.2K0.58%